KPTI - Karyopharm Therapeutics Inc
IEX Last Trade
0.7593
-0.012 -1.515%
Share volume: 481,269
Last Updated: Fri 30 Aug 2024 09:53:18 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$0.77
-0.01
-1.49%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-04 | 2022-11-03 | 2023-02-17 | 2023-05-04 | 2023-08-02 | 2023-11-02 | 2024-02-29 | 2024-05-08 | |
| Assets | |||||||||
| Total Assets | 256.478 M | 231.236 M | 358.172 M | 325.800 M | 297.830 M | 269.960 M | 240.438 M | 204.458 M | |
| Current Assets | 242.447 M | 222.677 M | 350.162 M | 318.541 M | 291.381 M | 263.222 M | 233.921 M | 198.366 M | |
| Inventories | 3.470 M | 4.249 M | 4.224 M | 3.827 M | 3.672 M | 3.105 M | 3.043 M | 2.769 M | |
| Other Current Assets | 43.506 M | 41.521 M | 19.821 M | 18.284 M | 18.097 M | 13.334 M | 11.813 M | 15.478 M | |
| Short Term Investments | 43.506 M | 41.521 M | 19.821 M | 18.284 M | 18.097 M | 13.334 M | 11.813 M | 15.478 M | |
| Total Receivables | 23.479 M | 27.446 M | 47.086 M | 35.200 M | 32.280 M | 37.923 M | 26.962 M | 31.082 M | |
| Current Cash | 170.846 M | 148.381 M | 277.967 M | 260.384 M | 236.765 M | 208.315 M | 191.443 M | 148.578 M | |
| Total Non-current Assets | 14.031 M | 8.559 M | 8.010 M | 7.259 M | 6.449 M | 6.738 M | 6.517 M | 6.092 M | |
| Property Plant Equipment | 1.395 M | 1.252 M | 1.139 M | 849.000 K | 766.000 K | 686.000 K | 606.000 K | 719.000 K | |
| Other Assets | 12.005 M | 6.681 M | 6.238 M | 5.776 M | 5.296 M | 5.671 M | 5.610 M | 5.069 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 256.478 M | 231.236 M | 358.172 M | 325.800 M | 297.830 M | 269.960 M | 240.438 M | 204.458 M | |
| Total liabilities | 372.816 M | 371.516 M | 374.828 M | 370.974 M | 369.078 M | 370.356 M | 376.644 M | 373.413 M | |
| Total current liabilities | 62.541 M | 61.761 M | 65.908 M | 61.555 M | 58.928 M | 62.079 M | 69.479 M | 65.341 M | |
| Accounts Payable | 1.694 M | 813.000 K | 2.773 M | 9.045 M | 2.287 M | 943.000 K | 3.123 M | 5.028 M | |
| Other liabilities | 0.000 | 0.000 | 0.000 | 1.085 M | 2.435 M | 1.428 M | 978.000 K | 2.582 M | |
| Current long term debt | 2.615 M | 2.770 M | 2.872 M | 2.977 M | 3.084 M | 3.195 M | 3.308 M | 3.425 M | |
| Long term debt | 310.275 M | 309.755 M | 308.920 M | 308.334 M | 307.715 M | 306.849 M | 306.187 M | 305.490 M | |
| Other liabilities | 0.000 | 0.000 | 0.000 | 1.085 M | 2.435 M | 1.428 M | 978.000 K | 2.582 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | -116.338 M | -140.280 M | -16.656 M | -45.174 M | -71.248 M | -100.396 M | -136.206 M | -168.955 M | |
| Common stock | 79.651 M | 80.210 M | 90.053 M | 113.481 M | 114.207 M | 114.401 M | 114.795 M | 115.454 M | |
| Retained earnings | -1.269 B | -1.305 B | -1.344 B | -1.378 B | -1.411 B | -1.445 B | -1.487 B | -1.524 B |